Paid Clinical Trials in Oregon

Oregon has 1,195 paid clinical trials enrolling now across cities including Portland, Eugene and Bend. Search by condition, age, or phase to find compensated research studies accepting participants near you.

Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 14, 2026.

Filter results

State

City

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

1,066 clinical trials

Get a weekly email when new trials open in Portland, OR.

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

Sites in Portland, Eugene +59 more locations

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for PIK3CA Mutation

Sites in Portland +51 more locations

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06982521·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

for Bipolar I or II Disorder

Sites in Portland +45 more locations

Sponsor: AbbVie

Sex: All·Age: 18 - 65

Code: NCT07220460·Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

for Small Cell Lung Cancer

Sites in Eugene +25 more locations

Sponsor: Puma Biotechnology, Inc.

Sex: All·Age: 18+

Code: NCT06095505·Phase 2·Recruiting·Listed Oct 2023

Apply to this trial

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

for NSCLC (Non-small Cell Lung Cancer)

Drug: daraxonrasib

Sites in Eugene +42 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06881784·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

for Endometrial Cancer

Sites in Eugene +46 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT06952504·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

for Alzheimer Disease

Sites in Portland +36 more locations

Sponsor: Lighthouse Pharmaceuticals, Inc.

Sex: All·Age: 55 - 80

Code: NCT06847321·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

for High-Risk Non-Muscle-Invasive Bladder Cancer

Sites in Portland, Springfield +73 more locations

Sponsor: CG Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06567743·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

Sites in Portland +40 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

for Lumbar Spinal Stenosis

Sites in Portland, Eugene +2386 more locations

Sponsor: Stryker Instruments

Sex: All·Age: 18+

Code: NCT03072927·Recruiting·Listed Mar 2017

Apply to this trial

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

for Epithelial Ovarian Cancer

Sites in Eugene, Tigard +67 more locations

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT06890338·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

for Ovarian Cancer

Sites in Eugene +26 more locations

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT07059845·Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

for Metastatic Colorectal Cancer

Sites in Salem +19 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT04929223·Phase 1·Recruiting·Listed Jun 2021

Apply to this trial

A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

for Ulcerative Colitis

Sites in Portland +76 more locations

Sponsor: Takeda

Sex: All·Age: 18 - 80

Code: NCT06581328·Phase 4·Recruiting·Listed Sep 2024

Apply to this trial

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

for Prostate Cancer Metastatic

Sites in Portland +32 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136624·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

for Breast Cancer

Sites in Medford, Tigard +47 more locations

Sponsor: Greenwich LifeSciences, Inc.

Sex: All·Age: 18 - 100

Code: NCT05232916·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

for Attention-Deficit/Hyperactivity Disorder

Sites in Gresham +46 more locations

Sponsor: Supernus Pharmaceuticals, Inc.

Sex: All·Age: 48 Months - 69 Months

Code: NCT04781140·Phase 4·Recruiting·Listed Mar 2021

Apply to this trial

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

for Non-Small Cell Lung Cancer

Drug: Divarasib

Sites in Portland +59 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06793215·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

for Acute Myeloid Leukemia (AML)

Sites in Eugene +41 more locations

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT07007312·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

Assessment of CCM in HF With Higher Ejection Fraction

for Heart Failure

Sites in Portland +75 more locations

Sponsor: Impulse Dynamics

Sex: All·Age: 18+

Code: NCT05064709·Recruiting·Listed Oct 2021

Apply to this trial

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for Diffuse Large B-Cell Lymphoma

Drug: Rituximab

Sites in Portland +47 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06717347·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

for Advanced Cancer

Sites in Portland +37 more locations

Sponsor: Artios Pharma Ltd

Sex: All·Age: 18+

Code: NCT04657068·Phase 1, Phase 2·Recruiting·Listed Dec 2020

Apply to this trial

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

for Psoriasis

Drug: Tirzepatide

Sites in Portland +38 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06857942·Phase 4·Recruiting·Listed Mar 2025

Apply to this trial

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

for Refractory Angina

Sites in Portland +65 more locations

Sponsor: Shockwave Medical, Inc.

Sex: All·Age: 18+

Code: NCT05102019·Recruiting·Listed Nov 2021

Apply to this trial

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

for Oligometastatic Prostate Cancer (OMPC)

Sites in Springfield +36 more locations

Sponsor: Novartis Pharmaceuticals

Sex: Male·Age: 18 - 100

Code: NCT05939414·Phase 3·Recruiting·Listed Jul 2023

Apply to this trial

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

for Leukemia, Myeloid, Acute

Drug: Venetoclax

Sites in Portland +55 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06852222·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

for Parkinson Disease

Sites in Portland +44 more locations

Sponsor: Neuron23 Inc.

Sex: All·Age: 40 - 80

Code: NCT06680830·Phase 2·Recruiting·Listed Nov 2024

Apply to this trial

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

for Glioma

Sites in Portland +45 more locations

Sponsor: Nuvation Bio Inc.

Sex: All·Age: 18+

Code: NCT05303519·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

for Cachexia

Drug: ponsegromab

Sites in Portland +82 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06989437·Phase 2, Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for Carcinoma, Non-Small-Cell Lung

Drug: Intismeran autogene

Sites in Corvallis +49 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06623422·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

for Low Grade Serous Ovarian Cancer

Drug: Avutometinib

Sites in Portland, Eugene +34 more locations

Sponsor: Verastem, Inc.

Sex: Female·Age: 18+

Code: NCT06072781·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

for Pancreatic Neuroendocrine Tumor (pNET)

Sites in Portland +39 more locations

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT06943755·Phase 2, Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

for Breast Neoplasms

Sites in Eugene +37 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06926868·Phase 2, Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

for Non-small Cell Lung Cancer

Drug: Intismeran autogene

Sites in Corvallis +57 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06077760·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain

for Pain

Sites in Eugene +11 more locations

Sponsor: Boston Scientific Corporation

Sex: All·Age: 18+

Code: NCT01719055·Recruiting·Listed Nov 2012

Apply to this trial

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

for Non Small Cell Lung Cancer

Sites in Portland +43 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312137·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

for Bronchiectasis

Sites in Portland +14 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 12+

Code: NCT06872892·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

for Ovarian Cancer

Sites in Eugene +34 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT06824467·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

for Non-Small Cell Lung Cancer

Sites in Portland +25 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07100080·Phase 2, Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

for Intermediate Risk Non-Muscle Invasive Bladder Cancer

Drug: Nadofaragene Firadenovec

Sites in Portland +49 more locations

Sponsor: Ferring Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06510374·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial